Metsera, Inc. (NASDAQ:MTSR – Get Free Report) shares were up 7.6% on Monday . The stock traded as high as $28.28 and last traded at $27.12. Approximately 40,441 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 557,944 shares. The stock had previously closed at $25.21.
Analyst Upgrades and Downgrades
MTSR has been the subject of several research reports. Evercore ISI initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Guggenheim began coverage on Metsera in a research note on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They set an “overweight” rating for the company.
View Our Latest Report on MTSR
Metsera Stock Performance
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
- Five stocks we like better than Metsera
- Trading Halts Explained
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Must-Own Stocks to Build Wealth This Decade
- The How and Why of Investing in Gold Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
